Etoposide-d3

CAT: 0804-HY-13629SSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-13629SSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Etoposide-d3 (VP-16-d3) is the deuterium labeled Etoposide (HY-13629) . Etoposide (VP-16) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].
Product Name Alternative
VP-16-d3; VP-16-213-d3
UNSPSC
12352005
Target
Antibiotic; Apoptosis; Autophagy; Bacterial; Isotope-Labeled Compounds; Mitophagy; Topoisomerase
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others
Field of Research
Cancer; Infection
Smiles
C[C@@H]1OC[C@]2([H])[C@@]([C@H](O)[C@@H](O)[C@H](O[C@@H]3C(C=C(OCO4)C4=C5)=C5[C@@H](C6=CC(OC)=C(O)C(OC([2H])([2H])[2H])=C6)[C@]7([H])[C@]3([H])COC7=O)O2)([H])O1
Molecular Formula
C29H29D3O13
Molecular Weight
591.58
References & Citations
[1]Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1 (4) :234-239.|[2]Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939.|[3]Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83 (11) : p. 2400-7.|[4]Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333 (16) 30147-3.|[5]Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30 (2) :497-509.e4.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products